LOGIN  |  REGISTER
Viking Therapeutics
Astria Therapeutics

R1 RCM to Present at the 42nd Annual J.P. Morgan Healthcare Conference

December 21, 2023 | Last Trade: US$14.23 0.00 0.00

MURRAY, Utah, Dec. 21, 2023 (GLOBE NEWSWIRE) -- R1 RCM Inc. (NASDAQ: RCM), a leading provider of technology-driven solutions that transform the patient experience and financial performance of healthcare providers, today announced its management team will present at the 42nd Annual J.P. Morgan Healthcare Conference on Tuesday, January 9, 2023, at 10:30am ET.

A live audio webcast of each presentation will be available on the Investor Relations section of R1’s website at r1rcm.com. A replay of the webcast will be available for 90 days following the live webcast.

About R1 RCM

R1 is a leading provider of technology-driven solutions that transform the patient experience and financial performance of hospitals, health systems, and medical groups. R1’s proven and scalable operating models seamlessly complement a healthcare organization’s infrastructure, quickly driving sustainable improvements to net patient revenue and cash flows while reducing operating costs and enhancing the patient experience. To learn more, visit: www.r1rcm.com

Contact:
R1 RCM Inc.

Investor Relations:
Evan Smith, CFA
516.743.5184
This email address is being protected from spambots. You need JavaScript enabled to view it. 

Media Relations:
Allison + Partners
Amanda Critelli
This email address is being protected from spambots. You need JavaScript enabled to view it. 

Recursion

Stock Quote

Featured Stock

Terns Pharmaceuticals

Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...

CLICK TO LEARN MORE

Featured Stock

Compass Therapeutics

Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page

COPYRIGHT ©2023 HEALTH STOCKS HUB